{"log_id": 8808561684887257561, "direction": 0, "words_result_num": 65, "words_result": [{"probability": {"variance": 0.000277, "average": 0.987804, "min": 0.954645}, "location": {"width": 44, "top": 20, "height": 14, "left": 177}, "words": "05月13"}, {"probability": {"variance": 0.028008, "average": 0.913241, "min": 0.470783}, "location": {"width": 154, "top": 35, "height": 16, "left": 66}, "words": "修改日期:2010年07月06"}, {"probability": {"variance": 0, "average": 0.999771, "min": 0.999597}, "location": {"width": 63, "top": 34, "height": 27, "left": 944}, "words": "益赛普"}, {"probability": {"variance": 0.006582, "average": 0.972663, "min": 0.64722}, "location": {"width": 478, "top": 76, "height": 37, "left": 71}, "words": "注射用重组人Ⅱ型肿瘤坏死因子受体一抗体融"}, {"probability": {"variance": 2e-05, "average": 0.99583, "min": 0.989694}, "location": {"width": 149, "top": 109, "height": 26, "left": 72}, "words": "合蛋白说明书"}, {"probability": {"variance": 0.023396, "average": 0.901607, "min": 0.477416}, "location": {"width": 285, "top": 153, "height": 22, "left": 72}, "words": "请仔纽阅读说明书并在医师指导下使用"}, {"probability": {"variance": 0.000713, "average": 0.984014, "min": 0.925096}, "location": {"width": 86, "top": 180, "height": 19, "left": 59}, "words": "【药品名称】"}, {"probability": {"variance": 0.003651, "average": 0.977898, "min": 0.69961}, "location": {"width": 502, "top": 202, "height": 30, "left": 99}, "words": "通用名称:注射用重组人Ⅱ型肿瘤坏死因子受体一抗体融合蛋白"}, {"probability": {"variance": 0.001002, "average": 0.963182, "min": 0.911513}, "location": {"width": 761, "top": 225, "height": 33, "left": 98}, "words": "汉语拼音: Zhusheyong Chongzu Ren Erxing Zhongliuhuaisiyinzi Shouti- Kangti Ronghedanbai"}, {"probability": {"variance": 0.003897, "average": 0.956782, "min": 0.812664}, "location": {"width": 143, "top": 248, "height": 21, "left": 98}, "words": "商品名:益赛普"}, {"probability": {"variance": 0.066679, "average": 0.859027, "min": 0.126403}, "location": {"width": 832, "top": 268, "height": 36, "left": 97}, "words": " 2: Recombinant Human Tumor Necrosis factor-o Receptor ll: IGG Fc Fusion Protein for Injecti"}, {"probability": {"variance": 0.000151, "average": 0.990216, "min": 0.969121}, "location": {"width": 58, "top": 295, "height": 20, "left": 57}, "words": "【成份】"}, {"probability": {"variance": 0.018642, "average": 0.923568, "min": 0.352691}, "location": {"width": 891, "top": 316, "height": 38, "left": 97}, "words": "主要组成成分每支含重组人口型肿林死因千受体一抗体融合蛋白 n TNFR:Fe)12.5毫克或25毫克,甘露40"}, {"probability": {"variance": 0.019603, "average": 0.91353, "min": 0.514993}, "location": {"width": 366, "top": 338, "height": 28, "left": 56}, "words": "毫克,蔗糖10毫克,二羟甲基氨基甲烷12毫克"}, {"probability": {"variance": 1.6e-05, "average": 0.995276, "min": 0.989836}, "location": {"width": 56, "top": 363, "height": 19, "left": 55}, "words": "【性状"}, {"probability": {"variance": 0.009765, "average": 0.967728, "min": 0.451621}, "location": {"width": 608, "top": 384, "height": 33, "left": 95}, "words": "本品为白色冻干粉针剂,加水溶解后溶液为无色或微带黄色的澄清,透明液体"}, {"probability": {"variance": 0.000206, "average": 0.984927, "min": 0.960781}, "location": {"width": 67, "top": 407, "height": 21, "left": 53}, "words": "【适应症"}, {"probability": {"variance": 0.000996, "average": 0.937467, "min": 0.909665}, "location": {"width": 53, "top": 452, "height": 20, "left": 54}, "words": "脊柱炎"}, {"probability": {"variance": 0.019741, "average": 0.93237, "min": 0.396089}, "location": {"width": 892, "top": 427, "height": 40, "left": 94}, "words": "用于治疗:1.中度及重度活动性类风湿关节炎;2.18岁及18岁以上成人中度及重度斑块状钱屑病:3活动性强直"}, {"probability": {"variance": 0.001095, "average": 0.979021, "min": 0.921756}, "location": {"width": 56, "top": 476, "height": 19, "left": 53}, "words": "【规格】"}, {"probability": {"variance": 0.005726, "average": 0.960626, "min": 0.554904}, "location": {"width": 702, "top": 494, "height": 37, "left": 94}, "words": "本品有两种规格:125mg支,活性为1.25×10AU/支:25mg支,活性为2.50×10AU支"}, {"probability": {"variance": 0.015121, "average": 0.931667, "min": 0.411638}, "location": {"width": 933, "top": 518, "height": 65, "left": 92}, "words": "皮下注射注射部位可为大腿腹部或上臂成人推荐剂量为每次25m,每周二次,每次间隔34 MACEU"}, {"probability": {"variance": 2e-06, "average": 0.997231, "min": 0.995127}, "location": {"width": 93, "top": 520, "height": 20, "left": 52}, "words": "【用法用量"}, {"probability": {"variance": 0.013716, "average": 0.944274, "min": 0.531769}, "location": {"width": 453, "top": 563, "height": 28, "left": 52}, "words": "毫升注射用水溶解,溶解后密闭坏境可于2-8℃冷藏72小时"}, {"probability": {"variance": 0, "average": 0.918242, "min": 0.918242}, "location": {"width": 19, "top": 559, "height": 18, "left": 938}, "words": "前"}, {"probability": {"variance": 1.1e-05, "average": 0.997501, "min": 0.990694}, "location": {"width": 95, "top": 586, "height": 19, "left": 49}, "words": "【不良反应】"}, {"probability": {"variance": 0.005017, "average": 0.865434, "min": 0.812511}, "location": {"width": 130, "top": 570, "height": 48, "left": 899}, "words": "业股份"}, {"probability": {"variance": 0.001249, "average": 0.98405, "min": 0.791589}, "location": {"width": 938, "top": 606, "height": 39, "left": 90}, "words": "常见不良反应是注射部位局部反应包括轻至中度红斑、搔痒、疼痛和肿胀等,注射部位反应通常发生在开始治疗"}, {"probability": {"variance": 0.010846, "average": 0.959949, "min": 0.441647}, "location": {"width": 916, "top": 628, "height": 37, "left": 49}, "words": "的第一个月内,在隐后的治疗中发生频率降低,注射部位反应平均持续35天,其它不良反应包括头痛、眩晕,皮疹"}, {"probability": {"variance": 0.016358, "average": 0.9408, "min": 0.441267}, "location": {"width": 915, "top": 651, "height": 37, "left": 50}, "words": "失眠、咳嗽、腹痛、上呼吸道感染,血压升高,外周血淋巴细思比例增多、鼻炎、发热、关节酸痛、肉酸痛、困倦"}, {"probability": {"variance": 0.029944, "average": 0.910914, "min": 0.371072}, "location": {"width": 338, "top": 676, "height": 22, "left": 49}, "words": "面部种胀、转酶升高等大部分无需处理"}, {"probability": {"variance": 0.002035, "average": 0.975544, "min": 0.806464}, "location": {"width": 403, "top": 698, "height": 26, "left": 89}, "words": "据国外文献报道,同类产品的不良反应还有如下报道"}, {"probability": {"variance": 2e-06, "average": 0.998162, "min": 0.996862}, "location": {"width": 37, "top": 720, "height": 19, "left": 47}, "words": "感染"}, {"probability": {"variance": 0.005716, "average": 0.980498, "min": 0.469225}, "location": {"width": 892, "top": 740, "height": 37, "left": 88}, "words": "最常见的感染是上呼吸道感染。在国外一项安慰剂对照试验中,严重感染的发生率没有明显升高开放性试验中严重感"}, {"probability": {"variance": 0.020617, "average": 0.930777, "min": 0.411988}, "location": {"width": 933, "top": 763, "height": 37, "left": 48}, "words": "染的发生率和对照试验中的发生比较也基本相似。发生严里感染的患者除了有RA外,还合并有其它问题如糖尿病、充"}, {"probability": {"variance": 0.017668, "average": 0.940076, "min": 0.454804}, "location": {"width": 587, "top": 787, "height": 28, "left": 48}, "words": "血性心衰,活动性或慢恢感染)国肉临床试验中没有发生严重感梁的报道"}, {"probability": {"variance": 1e-06, "average": 0.998883, "min": 0.9969}, "location": {"width": 72, "top": 810, "height": 19, "left": 47}, "words": "自身抗体"}, {"probability": {"variance": 0.008539, "average": 0.968716, "min": 0.520851}, "location": {"width": 891, "top": 829, "height": 38, "left": 87}, "words": "在国外的临床试验中,接受重组人口型肿瘤坏死因子受体一抗体融合蛋白治疗的患者中有ANA、抗双链DNA抗体"}, {"probability": {"variance": 0.020304, "average": 0.923121, "min": 0.428687}, "location": {"width": 914, "top": 852, "height": 37, "left": 46}, "words": "新发阳性的报道和甲氨蝶吟(MTX)组比较,新发自身抗体无明显差别,但长期应用重组人Ⅱ型瘤坏死因子受体"}, {"probability": {"variance": 0.010842, "average": 0.970306, "min": 0.517953}, "location": {"width": 376, "top": 875, "height": 27, "left": 46}, "words": "抗体融合蛋白对自身免疫性疾病的影响不清楚"}, {"probability": {"variance": 0.000533, "average": 0.969966, "min": 0.944251}, "location": {"width": 74, "top": 898, "height": 21, "left": 43}, "words": "恶性肿瘤"}, {"probability": {"variance": 0.012629, "average": 0.961791, "min": 0.364174}, "location": {"width": 890, "top": 919, "height": 36, "left": 88}, "words": "国外在接受重组人Ⅱ型肿疼坏死因子受体一抗体合蛋白治疗的患者中,观察到有极个别淋巴瘤发生,发生率的高"}, {"probability": {"variance": 0.008874, "average": 0.966445, "min": 0.456355}, "location": {"width": 934, "top": 941, "height": 37, "left": 43}, "words": "低和美风湿关节炎病情严重程度有关,另外还有少量其它类型肿瘤发生,最常见的是结肠,乳腺、肺和前列腺肿,发"}, {"probability": {"variance": 0.022914, "average": 0.927132, "min": 0.524497}, "location": {"width": 214, "top": 966, "height": 20, "left": 43}, "words": "生率和类型同正常人群类似"}, {"probability": {"variance": 1.3e-05, "average": 0.994828, "min": 0.989746}, "location": {"width": 59, "top": 986, "height": 22, "left": 41}, "words": "【禁忌】"}, {"probability": {"variance": 0.014328, "average": 0.955494, "min": 0.523016}, "location": {"width": 519, "top": 1009, "height": 29, "left": 83}, "words": "败血症,活动性结核病患者、对本品或制剂中其他成分过敏者禁用"}, {"probability": {"variance": 0.000557, "average": 0.988748, "min": 0.935979}, "location": {"width": 89, "top": 1033, "height": 19, "left": 45}, "words": "【注意事项】"}, {"probability": {"variance": 0.015691, "average": 0.944526, "min": 0.52171}, "location": {"width": 863, "top": 1053, "height": 36, "left": 111}, "words": "外上市同类品种的使用中发生过严重的感染收血症、致死和危及生命的感染)、因此,如果患者有反复发"}, {"probability": {"variance": 0.016078, "average": 0.955028, "min": 0.476639}, "location": {"width": 568, "top": 1077, "height": 29, "left": 111}, "words": "作的感染病史或者有易导玫感染的潜供疾病时,在使用本品时应极为慎重"}, {"probability": {"variance": 0.019981, "average": 0.945043, "min": 0.402678}, "location": {"width": 894, "top": 1098, "height": 36, "left": 79}, "words": "2在使用本品过程中者出现上呼吸道反复感染重有其他明显感染倾向时,应及时到医院就诊,由医生根据具体"}, {"probability": {"variance": 1e-06, "average": 0.999057, "min": 0.997259}, "location": {"width": 107, "top": 1123, "height": 20, "left": 108}, "words": "情况指导治疗"}, {"probability": {"variance": 0.021137, "average": 0.922696, "min": 0.401678}, "location": {"width": 635, "top": 1142, "height": 32, "left": 78}, "words": "3.当发生严重感梁如糖尿病发感染,结核杆菌感染等时,患者应暂停使用本品"}, {"probability": {"variance": 0.019721, "average": 0.936195, "min": 0.432617}, "location": {"width": 892, "top": 1164, "height": 37, "left": 80}, "words": "4在使用本品的过程甲,应注意过敏反应的发生,包括血管性水肿,荨麻疹以及其他严重反应,因此一旦出现"}, {"probability": {"variance": 0.008105, "average": 0.969189, "min": 0.565798}, "location": {"width": 392, "top": 1190, "height": 24, "left": 105}, "words": "过敏反应,应立刻中止本品的治疗,并予适当处理"}, {"probability": {"variance": 0.009179, "average": 0.965322, "min": 0.501984}, "location": {"width": 894, "top": 1209, "height": 39, "left": 77}, "words": "5由于肿瘤坏死因子可调节炎症及细胞免疫反应,因此在使用本品时,应充分考虑到可能会影响患者的抗感染及"}, {"probability": {"variance": 0.029562, "average": 0.928232, "min": 0.507087}, "location": {"width": 125, "top": 1234, "height": 19, "left": 103}, "words": "恶性肿痛的作用"}, {"probability": {"variance": 0.010146, "average": 0.970357, "min": 0.41452}, "location": {"width": 764, "top": 1254, "height": 36, "left": 106}, "words": "目前尚无接受本品的患者在接种活疫苗后造成传播感染的数据但在使用本品期间不可接种活疫苗"}, {"probability": {"variance": 0.007137, "average": 0.971731, "min": 0.473243}, "location": {"width": 896, "top": 1276, "height": 39, "left": 75}, "words": "7.在向类品种上市后报道中发现有可能导致充血性心衰的病人病情恶化,因此对于有充血性心衰的患者在使用"}, {"probability": {"variance": 0.005839, "average": 0.95463, "min": 0.758595}, "location": {"width": 141, "top": 1302, "height": 19, "left": 105}, "words": "本品时应极为慎重"}, {"probability": {"variance": 0.000157, "average": 0.992638, "min": 0.95657}, "location": {"width": 200, "top": 1323, "height": 20, "left": 35}, "words": "【孕妇及哺乳期妇女用药】"}, {"probability": {"variance": 0.002197, "average": 0.980786, "min": 0.820915}, "location": {"width": 232, "top": 1345, "height": 23, "left": 77}, "words": "不建议孕妇及哺乳期妇女使用"}, {"probability": {"variance": 0.000269, "average": 0.989047, "min": 0.952999}, "location": {"width": 93, "top": 1367, "height": 21, "left": 34}, "words": "【儿童用药】"}, {"probability": {"variance": 0.000472, "average": 0.980482, "min": 0.943662}, "location": {"width": 61, "top": 1411, "height": 19, "left": 34}, "words": "3-4天"}, {"probability": {"variance": 0.013335, "average": 0.957142, "min": 0.445977}, "location": {"width": 892, "top": 1388, "height": 38, "left": 76}, "words": "尚元2岁以下儿童用药资料:国外报道儿童4至17岁)用药剂量为每周0.8mg/kg.每周剂量推荐分二次,每次间"}, {"probability": {"variance": 3e-06, "average": 0.998266, "min": 0.994927}, "location": {"width": 92, "top": 1434, "height": 20, "left": 34}, "words": "【老年用药"}], "language": 3}